The Neuropsychiatric Drug Development Summit annually unites 150+ biotech and pharma stakeholders, with functions spanning discovery, in vivo pharmacology, translational medicine, clinical development, medical, regulatory affairs and more, as well as leading academics, venture capitalists and solution providers, in one hyper-relevant and focused setting.
Across the 3 days, you’ll engage in deep-dive interactive workshops, roundtable discussions, data-driven presentations and structured networking activities to foster collaboration and gain the most recent insights to truly advance your pipeline of next generation neuropsychiatric therapeutics.
What's New for 2025?
EEG Biomarker Seminar Day
Optimize the use of EEG as a comprehensive & translational tool to guide your program through end-to-end development
Investor's Panel
Explore the catalysts driving deal-making momentum in neuropsychiatry and discover what investors are seeking from the next wave of readouts
Brand-New Presenting Companies
Including Reunion Neuroscience, Intra-Cellular Therapies, Seaport Therapeutics, Cybin, Kinoxis Therapeutics and many more
Find Out More in the Full Event Guide
- Learn more about this year's 40+ expert speakers
- Discover the all new EEG Focus Day & Investor's Panel
- Uncover the latest developments spanning depression, schizophrenia, anxiety, addiction and more
- Get a sneak preview of who will be attending this year's meeting
Who Will You Meet?
What Your Peers Have to Say
“I thought the topics of discussion were very timely and pertinent. I enjoyed the diversity of content through combination of large group talks, panel discussions, small seminars and roundtable discussions.”
Director, Alkermes
“Great to have so many pharma experts reunited to discuss bottle necks of neuropsychiatry R&D.”
External Innovation Manager, Boehringer Ingelheim